BioMarin Pharma (BMRN) – StreetInsider.com Reports
-
BioMarin Pharma (BMRN) April 80 puts active
-
BioMarin Pharma (BMRN) Appoints Cristin Hubbard as Chief Commercial Officer
-
BioMarin Pharma (BMRN) April 85 puts active
-
Increasing unusual option volume: SANA HUYA BMRN INDI CYH FTAI NU FTI
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $115 at Morgan Stanley
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $128 at Jefferies
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $107 at Piper Sandler
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $94 at Citi
-
BioMarin Pharma (BMRN) Tops Q4 EPS by 29c ; Offers Guidance
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $133 at Jefferies
-
BioMarin Pharma (BMRN) March 80 puts active
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $104 at Baird
-
BioMarin Pharma (BMRN) Announces Resignation of Chief Commercial Officer
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $93 at Bernstein
-
BioMarin Pharma (BMRN) Announces Governance Enhancements and Value Creation Initiatives
-
BioMarin Pharma (BMRN) Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN for Severe Hemophilia A in Germany
-
Wells Fargo Starts BioMarin Pharmaceutical Inc. (BMRN) at Overweight
-
Goldman explores intrinsic and takeover value of BioMarin amid Elliott stake
-
BioMarin Pharma (BMRN) gains on report Elliott has a stake
-
Activist Investor Elliott Takes Stake In Biomarin Pharmaceutical (BMRN), In Talks With Company About Its Future - Reuters
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $91 at Canaccord Genuity
-
BioMarin Pharma (BMRN) Announces CEO Resignation
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $170 at BofA Securities
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $117 at Morgan Stanley
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $119 at UBS
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $101 at Stifel
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $106 at Jefferies
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $125 at TD Cowen
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $83 at Scotiabank
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $100 at BMO Capital
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $100 at Cantor Fitzgerald
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $115 at Piper Sandler
-
BioMarin Pharma (BMRN) Tops Q3 EPS by 23c; offers guidance
-
BioMarin Pharma (BMRN) Announces CEO Retirement
-
Bernstein Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Market Perform
-
BioMarin Pharma (BMRN) Announces FDA Approval of VOXZOGO for Children Under 5 Years with Achondroplasia
-
Increasing unusual option volume
-
Raymond James Starts BioMarin Pharmaceutical Inc. (BMRN) at Market Perform, 'Cautious on Roctavian's Outlook & Few Near-Term Catalysts'
-
UBS Starts BioMarin Pharmaceutical Inc. (BMRN) at Buy, 'Undervalued sustainable profits'
-
BioMarin Pharma (BMRN) Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO to Treat Children Aged 4 Months and Older with Achondroplasia
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $125 at Morgan Stanley
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $108 at Stifel
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $70 at Wedbush
-
BioMarin Pharma (BMRN) Tops Q2 EPS by 31c, Offers Guidance
-
Scotiabank Starts BioMarin Pharmaceutical Inc. (BMRN) at Sector Perform
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $185 at BofA Securities
-
BioMarin (BMRN) Dropped from BofA Securities Best Ideas List
-
BioMarin Pharma (BMRN) rises on BMO upgrade to Outperform
-
BMO Capital Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Outperform, 'Current Valuation Skews Risk/Reward to Upside'
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $104 at Canaccord Genuity
Back to BMRN Stock Lookup